Levosert Shi

Levonorgestrel, the active ingredient in Levosert Shi, is a progestogen (progestin) presented as an intrauterine system (IUS) for intrauterine use. It delivers levonorgestrel locally to provide long‑acting reversible contraception and to reduce heavy menstrual bleeding in women of reproductive age.

GNH USA supplies Levosert Shi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution channels that meet EU regulatory standards and rigorous quality‑assurance processes.

Levosert Shi, a levonorgestrel‑releasing intrauterine system, is indicated for the following clinical uses:

- Long‑acting reversible contraception: provides effective contraception for up to five years. - Heavy menstrual bleeding: reduces menstrual blood loss and improves anemia associated with excessive bleeding.

Levosert Shi may cause a range of adverse reactions. Monitoring and patient counseling are recommended.

Common Side Effects: - Irregular bleeding or spotting: unpredictable menstrual patterns. - Amenorrhea: absence of periods after initial adjustment. - Pelvic or cramping pain: discomfort during the first months. - Breast tenderness: mild hormonal effect on breast tissue. - Headache: occasional tension‑type headache. - Acne or skin changes: mild hormonal skin response.

Serious or Rare Side Effects: - Uterine perforation: rare injury during insertion. - Device expulsion: loss of the IUS from the uterine cavity. - Pelvic infection: potential for bacterial infection post‑insertion. - Ectopic pregnancy: pregnancy occurring outside the uterus if contraception fails. - Severe allergic reaction: anaphylaxis or hypersensitivity to device components. - Thromboembolic events: rare clotting disorders linked to systemic hormone exposure.

Prior to insertion, clinicians should assess patient suitability and counsel on expected changes.

- Contraindications: pregnancy, suspected pregnancy, active pelvic infection, unexplained vaginal bleeding, uterine anomalies, or known malignancy. - Insertion by trained professional: ensure correct placement to minimize perforation risk. - Follow‑up evaluation: schedule visits to confirm device position and address adverse symptoms. - Menstrual changes: inform patients that spotting or amenorrhea are common early effects. - Interaction with hormonal therapies: review concurrent hormonal medications. - Store at room temperature below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Levosert Shi may interact with medications that alter hormone metabolism or affect bleeding risk.

Major Interactions (Avoid): - Enzyme inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort): may reduce levonorgestrel effectiveness. - Antifungal agents (e.g., griseofulvin): can lower hormone levels. - Certain antiretrovirals (e.g., efavirenz): may diminish contraceptive efficacy.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may increase bleeding tendency. - NSAIDs (e.g., ibuprofen): can exacerbate spotting. - Hormonal therapies (e.g., estrogen‑containing pills): may alter bleeding patterns. - Antidepressants (e.g., SSRIs): occasional reports of increased spotting. - Herbal supplements (e.g., ginseng): potential modest effect on hormone metabolism.